Utilizing ectopic Hsp90 expression to diagnose breast cancer at the point-of-care using fluorescence microscopy
June 2-6, 2019
Although pathological examination serves as the gold standard for breast cancer diagnosis, it requires labor-intensive sample preparation and time-consuming evaluation, resulting in long turn-around time and extensive infrastructure. We have developed a simple molecular imaging platform that can quickly assess patient’s samples and provide a molecular signal to reflect disease pathology as an alternative to traditional pathology, particularly for applications in low resource settings. We identified Heat shock protein 90 (Hsp90) as a molecular target to diagnose breast cancer as it is overexpressed on the surface of all breast cancer cell subtypes to orchestrate stress response to cancer formation. Based on this feature, we have established a non-invasive and rapid molecular imaging approach to quantify Hsp90 expression on breast tissue biopsies using a FITC tethered Hsp90 inhibitor (HS-27) that binds to surface Hsp90 of breast cancer cells. A wide-field, high resolution, handheld fluorescent microscope referred to as the Pocket Mammoscope has been developed to perform rapid non-contact Hsp90 fluorescent imaging of entire tissue biopsies at point of care.
Please click Additional Files below to see the full abstract.
Roujia Wang, Brian Crouch, Christopher Lam, Jenna Muller, Nimmi Ramanujam, Timothy Haystead, and Philip Hughes, "Utilizing ectopic Hsp90 expression to diagnose breast cancer at the point-of-care using fluorescence microscopy" in "Advances in Optics for Biotechnology, Medicine and Surgery XVI", Erin Buckley, Emory University/Georgia Institute of Technology, USA Christophe Moser, Polytechnique Fédérale de Lausanne (EPFL), Switzerland Brian Pogue, Dartmouth College, USA David Sampson, University of Western Australia, Australia Eds, ECI Symposium Series, (2019). https://dc.engconfintl.org/biotech_med_xvi/16